I am a fellow in therapeutic sciences in the Laboratory of Systems Pharmacology (LSP) at Harvard Medical School. My current research is focused on the beneficial effect of polypharmacology in therapeutic drugs in the areas of neurology and neuropsychiatry. My research is currently focused on improving the pharmacological treatments of pain and major depressive disorder (MDD), both of which have a great unmet medical need. I use both computational and experimental approaches to improve our understanding of the biological mechanisms underlying pain and MDD. It is my ultimate goal to improve the standard of care for both conditions.
I received my PhD in Chemical Biology from Harvard Univeristy in 2018 under the guidance of Peter Sorger, Christoph Benoist and Jeremy Jenkins. I embarked on my PhD journey by studying how small molecules can modulate the activation of conventional and regulatory CD4 positive Tcells. This work brought to bear the importance of considering polypharmacology of small molecules when studying their effects. I continued to focus my efforts on unraveling small molecule polypharmacology and its role in drug development, which culminated in the finding that almost all approved drugs show polypharmacology and only few of them seem to be selective. I enriched my PhD experience with an extensive internship at the Novartis Institute for biomedical research and also explored the commercialization of science as a resident at the innovation lab of the Harvard Business School. Prior to my PhD at Harvard I completed a bachelors in Chemistry and a bachelors in Pharmaceutical Sciences at the VU university in Amsterdam.<embed>